Curanex Pharmaceuticals (CURX) EBT (2024 - 2026)

Curanex Pharmaceuticals (CURX) has reported EBT for 3 consecutive years, with -$3.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 5374.26% year-over-year to -$3.3 million; the trailing twelve-month figure through Jun 2026 stood at -$7.4 million (changed N/A YoY), and the FY2025 full-year result was -$4.2 million, down 1063.53% from the prior year.
• EBT retreated to -$3.3 million in Q2 2026 per CURX's latest filing, from -$3.1 million in the prior quarter.
• Across five years, EBT topped out at -$60749.0 in Q2 2025 and bottomed at -$3.3 million in Q2 2026.
• Historically, EBT has averaged -$1.3 million across 3 years, with a median of -$551391.5 in 2024.
• The sharpest annual moves came in 2025 and 2026: EBT slumped 924.08% in 2025, then tumbled 5374.26% in 2026.
• Over 3 years, EBT stood at -$147366.0 in 2024, then sank by 1998.61% to -$3.1 million in 2025, then retreated by 7.53% to -$3.3 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$3.3 million, -$3.1 million, and -$955417.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.